Back to list

Foresite Capital Management

Foresite Capital is a multi-stage healthcare and life sciences investment firm that applies rigorous scientific and data-driven approaches to investment analysis. The firm has $2 billion under management. Foresite Capital takes a collaborative approach to investing with its portfolio companies by providing a multidisciplinary team of scientists, engineers, analysts, and clinicians who understand the unique business models in healthcare in addition to capital. The company aims to address areas of great unmet clinical need over the long term by funding promising healthcare and life sciences businesses at all stages of their life cycles. Its portfolio also emphasizes companies that are employing the tools of data science and machine intelligence in healthcare. Foresite Capital is based in San Francisco with an office in New York.

Vikram Bajaj

MD

Matthew Buten

MD

SK

Shoman Kasbekar

Senior Investment Analyst

RK

Rhonda Kaufman

Director

Richard Lau

Partner

AM

Alisa Mall

MD

Dorothy Margolskee

MD

Stephen C. Peterson

Director

HR

Hemaka Rajapakse

Director

Michael Rome

MD

Dennis Ryan

CFO and MD

Damien Soghoian

Director

Jim Tananbaum

Founder and CEO

Cindy Xiong

Director

Brett Zbar

Managing Partner

131 past transactions

Sestina Bio

Seed Round in 2020
At Sestina Bio, LLC their mission is to create a technology centric, R&D platform that will tackle some of the largest challenges of the 21st century and provide cutting edge solutions to sustainably feed, clothe, and keep healthy the growing world population. their approach is to integrate, and where needed create, the most innovative and novel advances in synthetic biology, data sciences, and bio-analytical systems.

Inscripta, Inc

Series C in 2019
Inscripta, Inc. operates as a gene editing technology company. The company engages in developing CRISPR enzymes (MADzymes) for precision gene editing. Inscripta, Inc. was formerly known as Muse Biotechnology, Inc. The company was founded in 2015 and is based in Boulder, Colorado. It has additional offices in Pleasanton and San Diego, California.

23andMe

Post in 2021
23andMe, Inc. provides consumer genetics and research services. The company offers DNA analysis services through home-based saliva collection kit for consumers to access and understand the human genome. Its services include Health + Ancestry, a genetic insight into ancestry, traits, and health; and Ancestry + Traits, a DNA kit with an ancestry breakdown and 30+ trait reports. The company was founded in 2006 and is based in Sunnyvale, California. With an additional office in Mountain View, California.
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom.
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.

Evonetix Ltd

Series B in 2023
evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniques we are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines.

Cerevance

Series B in 2023
Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle the early onset of various neurological diseases.

Gemini Therapeutics

Post in 2021
Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.Their therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world,they are developing a series of potentially first-in-class therapeutics.

Kriya Therapeutics, Inc.

Series B in 2021
Kriya Therapeutics, Inc., a gene therapy company, focuses on designing and developing treatments for chronic diseases. It also offers vector design, manufacturing, and clinical development solutions. Kriya Therapeutics, Inc. was incorporated in 2019 and is based in Palo Alto, California with an additional office in Durham, North Carolina.

Aetion

Series C in 2021
Aetion, Inc. develops a science and analytics platform to assess real-world evidence (RWE) from a range of sources. The company offers Aetion Evidence Platform, a platform that generates RWE needed by healthcare decision makers to engage in value-based care. Its solution allows payers, providers, medical device makers, biopharma customers, and academic institutions to analyze data from various clinical and financial interactions in healthcare, including claims, electronic health records, registries, and clinical trials. The company’s platform is also used in database analytics and comparative effectiveness courses taken by epidemiologists, outcomes researchers, health economists, and biostatisticians. It serves customers worldwide. Aetion, Inc. has a strategic collaboration with McKesson. The company was founded in 2012 and is based in New York, New York.

Interline Therapeutics

Series A in 2021
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities. It uses genomics, proteomics, structural biology, and computational chemistry to map and modulate protein communities. Interline leverages recent advancements in these technologies, as well as collaborations with leading academic groups, to develop a precision medicine platform focused on three essential areas, genomics, communities, and modulators. The South San Francisco, California-located company was founded by Zach Sweeney in 2020.

Alector

Series E in 2018
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer’s disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

Sage Therapeutics, Inc.

Series C in 2014
SAGE Therapeutics is dedicated to the health and well being of patients with central nervous system (CNS) disorders. Their mission is to discover, develop and deliver novel medicines for many of today's most debilitating and disabling CNS disorders by leveraging compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers.

Genomics PLC

Venture Round in 2021
Genomics PLC develops algorithms and software solutions that focus on cancer, microbes, and rare diseases. Its solutions allow governments and healthcare providers to transform healthcare provisions for their citizens and members; pharmaceutical and biotechnology clients to de-risk the drug development process; clinicians and doctors to improve diagnoses and treatment options; and research laboratories and genome analysts to process results accurately. The company was incorporated in 2014 and is based in Oxford, United Kingdom.

Esker Therapeutics

Series A in 2021
Esker is a precision medicines company looking to eliminate the “all-comers” approach that is seen with today’s treatments for people with autoimmune disease. Even with the innovation of the last decade, many patients continue to cycle through the approved therapies while continuing to look for the right therapy to alleviate the impact of their disease without life-impacting side effects. Esker leverages a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug development and immunology, in order to create medicines that change the lives of people with autoimmune disease.

XinThera

Series B in 2021
XinThera is a drug discovery company focused on building small molecule oncology and immunology pipeline.

Crossover Health

Series D in 2021
Crossover Health, Inc. provides workplace healthcare services for employers and employees in companies. It offers primary, ancillary, and advanced services, including urgent care, preventive care, chronic disease management, health risk assessment, health education, health coaching, biometrics, physical therapy, chiropractic, acupuncture, specialist preferred network, care coordination, health analytics, and remote care. The company was founded in 2010 and is headquartered in Aliso Viejo, California with health centers in Silicon Valley, as well as in other locations in the United States.

Element Biosciences, Inc.

Series B in 2020
Element Biosciences, Inc. develops genetic analysis tools for the research and diagnostic markets. The company provides a disruptive DNA sequencing technology and a sequencing platform, such as surface chemistry, sequencing chemistry, detection, and data analysis. The company was incorporated in 2017 and is based in San Diego, California.

Pardes Biosciences

Post in 2021
Pardes Biosciences is a biotechnology company that develops and commercializes direct-acting antivirals for the treatment of coronavirus. The Carlsbad, California-based company was established by Uri Lopatin in 2020.

Mythic Therapeutics

Series B in 2021
Mythic Therapeutics is a biotechnology company focused on a new generation of groundbreaking cancer therapeutics. The company is pioneering a powerful protein engineering-focused approach to improving the effectiveness of antibody-drug conjugates (ADCs) and other antibody-based therapeutics. Their technology dramatically increases therapeutic potency without compromising safety, thereby unlocking the full potential of targeted therapies against a broad array of tumor targets. Mythic Therapeutics was founded in 2017 and is headquartered in Waltham, MA, USA.

Mammoth Biosciences

Series D in 2021
Mammoth Biosciences, Inc., a biotechnology company, develops clustered regularly interspaced short palindromic repeats (CRISPR0 solutions. It offers DETECTRTM that searches for the presence of specific nucleic acids in a sample that are indicative of disease, providing actionable clinical information for various diagnostic applications, such as single nucleotide polymorphisms (SNP), bacterial infections, cancer screening and profiling, antimicrobial resistance, and viral infections. The company also provides CRISPR-Cas systems to edit the genome for therapeutic applications, including immuno-oncology, autoimmune diseases, and liver diseases. Its solutions are used in healthcare, agriculture, environmental monitoring, biodefense, and other applications. Mammoth Biosciences, Inc. was formerly known as Apheleia Diagnostics, Inc. The company was founded in 2017 and is based in South San Francisco, California.

ImmPACT Bio USA

Series B in 2022
ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.

Mindstrong Inc.

Series A in 2017
Mindstrong Health develops comprehensive care pathways based on passively-collected, continuous and objective measures of cognitive function and mood. Solutions include a patient-facing app, a provider-facing product, and clinical services that leverage its telehealth enabled measurement science and engagement platform. Mindstrong is partnered with leading organizations committed to advancing medical innovation and improving healthcare delivery for patients, including pharmaceutical companies, large payers and providers, large employers, and state and county governments, in addition to top-tier academic institutions for clinical research.

Mirvie

Series B in 2022
Mirvie is a biotech company that creates precise, actionable, and non-invasive tests for maternal-fetal health. The company delivers insights to moms and families to make pregnancy safe. It was founded in 2018 by Maneesh Jain and is headquartered in South San Francisco, California, United States.

Kriya Therapeutics, Inc.

Series C in 2022
Kriya Therapeutics, Inc., a gene therapy company, focuses on designing and developing treatments for chronic diseases. It also offers vector design, manufacturing, and clinical development solutions. Kriya Therapeutics, Inc. was incorporated in 2019 and is based in Palo Alto, California with an additional office in Durham, North Carolina.

Tesseract Health

Series B in 2021
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company’s second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.

Kriya Therapeutics, Inc.

Series A in 2020
Kriya Therapeutics, Inc., a gene therapy company, focuses on designing and developing treatments for chronic diseases. It also offers vector design, manufacturing, and clinical development solutions. Kriya Therapeutics, Inc. was incorporated in 2019 and is based in Palo Alto, California with an additional office in Durham, North Carolina.

REGENXBIO

Series D in 2015
REGENX Biosciences, LLC, a biopharmaceutical company, develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. The company offers NAV, a gene delivery technology that includes recombinant adeno-associated viral vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, hematologic disorders, ocular diseases, and neurodegenerative disorders; and clinical trails in therapeutic areas, such as inherited diseases, CNS disorders, heart failure, and vaccines. The company also offers reagent services for various applications, including molecular therapies, understanding biological activity and target validation, creating disease models and screening in vivo, and genome-wide association studies. In addition, it offers custom products and services, including AAV plasmids, AAV Vector reporter systems, and custom AAV vectors to the researchers. The company is based in Washington, District Of Columbia.

Maze Therapeutics

Venture Round in 2022
Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines. The company's translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, functional genomics and an array of drug discovery approaches.and its also reveals modifier genes that confer protection and provides deeper understanding of the target biology and how these targets can be targeted with drug therapies, enabling patients with protection against diseases.

Arcus Biosciences, Inc.

Series B in 2016
Arcus Biosciences is biotech company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. Arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the San Francisco bay area, in the heart of the world’s largest biotechnology research hub.

Element Biosciences, Inc.

Series A in 2019
Element Biosciences, Inc. develops genetic analysis tools for the research and diagnostic markets. The company provides a disruptive DNA sequencing technology and a sequencing platform, such as surface chemistry, sequencing chemistry, detection, and data analysis. The company was incorporated in 2017 and is based in San Diego, California.

Insitro

Series A in 2019
Insitro is a operator of a data-driven drug discovery and development company that uses machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company uses state-of-the-art technologies from Bioengineering enabling it to generate high-throughput, functional genomic data sets and aligning them with patient data via a novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.

Remix Therapeutics

Series B in 2022
Remix Therapeutics Inc. engages in the biotech research and development business. It discovers and develops various novel therapeutic RNA processing modulators to target various undruggable disease drivers. The company also offers biology platform to identify and prioritize targets with therapeutically-tractable intervention points in RNA processing. Its REMseq platform validates targets and chemical matter discovery and optimization. The company was founded in 2018 and is based in Cambridge, Massachusetts.

Karyopharm Therapeutics

Series B in 2013
Karyopharm Therapeutics is a biopharmaceutical company focusing on the development of novel drugs for the treatment of cancer, inflammation and diseases related to cell proliferation. Karyopharm Therapeutics is developing small molecule drugs that will modulate the activity of critical pathways in cancer, inflammation, and cell proliferation (e.g. FOXO, NFкB, P53, pRB) by targeting the nuclear pore complex machinery, which controls the import and export of proteins between the nucleus and cytoplasm. To successfully control transport through the nuclear pore complex, the company will use its unique technology platform, developed by Sharon Shacham, to identify novel small molecules, optimize them into clinical candidates, and to evaluate them in subsequent human clinical studies.

Pharvaris B.V.

Series B in 2019
Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study. The co-founders of Pharvaris include an inventor of icatibant and the leadership from Jerini AG that developed icatibant for the treatment of HAE, now sold by Takeda under the brand name Firazyr®.

Element Biosciences, Inc.

Series C in 2021
Element Biosciences, Inc. develops genetic analysis tools for the research and diagnostic markets. The company provides a disruptive DNA sequencing technology and a sequencing platform, such as surface chemistry, sequencing chemistry, detection, and data analysis. The company was incorporated in 2017 and is based in San Diego, California.

Generation Bio Co.

Series B in 2018
Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was founded in 2016 and is headquartered in Cambridge, Massachusetts.

DNAnexus

Series H in 2022
DNAnexus combines expertise in cloud computing and bioinformatics to create the global network for genomic medicine. DNAnexus provides security, scalability and collaboration for enterprises and organizations that are pursuing genomic-based approaches to health in order to accelerate medical discovery. DNAnexus is supporting customers around the world that are tackling some of the most challenging and exciting opportunities in human health. It was founded in 2009 and is based in Mountain View, California.

Generation Bio Co.

Series C in 2020
Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was founded in 2016 and is headquartered in Cambridge, Massachusetts.

Ivantis Inc.

Series B in 2014
Ivantis, Inc. is a company focused on developing an innovative treatment for Glaucoma. It is their goal to develop a less invasive, more effective option for the 60+ million people worldwide suffering from Primary Open Angle Glaucoma. As they successfully address this initial goal, it is then there intention to focus on innovative development for the treatment of other debilitating diseases within ophthalmology.

Odyssey Therapeutics

Series A in 2021

Tango Therapeutics

Post in 2021
Tango Therapeutics, Inc., a biotechnology company, develops cancer drugs based on synthetic lethality. The company uses the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer. It focuses counteracting tumor suppressor gene loss; reversing the ability of cancer cells to evade the immune system; and identifying novel combinations that are more effective than single agent therapy. Tango Therapeutics, Inc. was formerly known as Cancer Combos NewCo, Inc. The company was incorporated in 2014 and is based in Cambridge, Massachusetts.

Quantum SI

Post in 2021
Quantum-Si has created a very unique environment where bright, highly committed individuals are given the freedom, ownership, and resources to solve tough problems and be the first to do new science. Quantum-Si is fully-funded by successful founders so employees can focus on creating, building, learning, and getting to market products that will change the world.

Cue Health Inc.

Series C in 2020
Cue is a revolutionary device for tracking health information at the molecular level. For the first time, consumers can track 5 key health and lifestyle indicators: inflammation, vitamin D, fertility, influenza, and testosterone in just minutes, at home. Cue sends the data via Bluetooth 4.0 to the user's smartphone, where the free Cue app reveals the interplay of activity, food, and sleep shaping the user at a molecular level.

Elpis BioMed

Series B in 2021
Elpis Biomed aims to become a leading, global supplier of in vitro cell types for academic research and commercial drug discovery & development purposes. The cells could provide an alternative to the limited supply of primary cells and replace animal studies in other cases. Elpis Biomed’s proprietary technology allows rapid generation of highly mature, differentiated cell types at unmatched purity. The process is scalable with the potential to expand product offering with additional cell-types in the neuro-mesoderm focus area. Initial products will be cortical neurons, oligodendrocytes and skeletal muscle cells to be sold to academic research groups and pharma/biotech customers.

HealthVerity

Series D in 2021
HealthVerity is a provider of technologies and software tools that enable healthcare providers, such as Pharmaceutical manufacturers, Hospitals and Payers, to discover, license and integrate patient data from a wide range of traditional and emerging data sources to build the optimal patient data set. It serves as the foundation for the rapid creation, exchange, and management of healthcare and consumer data in a fully-interoperable, privacy-protecting manner. Advantaged by highly sophisticated identity resolution and matching capabilities, HealthVerity aims to increase transparency and activate deeper insights across the healthcare industry. It was founded in 2014 and is headquartered in Philadelphia, Pennsylvania.

TenSixteen Bio

Series A in 2022

Insitro

Series C in 2021
Insitro is a operator of a data-driven drug discovery and development company that uses machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company uses state-of-the-art technologies from Bioengineering enabling it to generate high-throughput, functional genomic data sets and aligning them with patient data via a novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.

Myome

Series B in 2022
Myome helps identify genes that cause disease and act based on leading science. The data is secure, portable, and reusable throughout life.
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.

Adagio Therapeutics, Inc.

Series C in 2021
Adagio Therapeutics, Inc., a biotechnology company, develops antibodies that neutralize SARS-CoV-2, SARS-CoV-1, and potentially emergent coronaviruses. Its portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Inscripta, Inc

Series C in 2019
Inscripta, Inc. operates as a gene editing technology company. The company engages in developing CRISPR enzymes (MADzymes) for precision gene editing. Inscripta, Inc. was formerly known as Muse Biotechnology, Inc. The company was founded in 2015 and is based in Boulder, Colorado. It has additional offices in Pleasanton and San Diego, California.

Insitro

Series B in 2020
Insitro is a operator of a data-driven drug discovery and development company that uses machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company uses state-of-the-art technologies from Bioengineering enabling it to generate high-throughput, functional genomic data sets and aligning them with patient data via a novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.

Eikon Therapeutics

Series A in 2021
Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells.

Interline Therapeutics

Seed Round in 2021
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities. It uses genomics, proteomics, structural biology, and computational chemistry to map and modulate protein communities. Interline leverages recent advancements in these technologies, as well as collaborations with leading academic groups, to develop a precision medicine platform focused on three essential areas, genomics, communities, and modulators. The South San Francisco, California-located company was founded by Zach Sweeney in 2020.

Cue Health Inc.

Series C in 2020
Cue is a revolutionary device for tracking health information at the molecular level. For the first time, consumers can track 5 key health and lifestyle indicators: inflammation, vitamin D, fertility, influenza, and testosterone in just minutes, at home. Cue sends the data via Bluetooth 4.0 to the user's smartphone, where the free Cue app reveals the interplay of activity, food, and sleep shaping the user at a molecular level.

Inscripta, Inc

Series E in 2021
Inscripta, Inc. operates as a gene editing technology company. The company engages in developing CRISPR enzymes (MADzymes) for precision gene editing. Inscripta, Inc. was formerly known as Muse Biotechnology, Inc. The company was founded in 2015 and is based in Boulder, Colorado. It has additional offices in Pleasanton and San Diego, California.

PACT Pharma, Inc.

Series C in 2020
Pact Pharma is a developer of personalized adoptive T cell therapies designed for the eradication of solid tumors.The company's therapies help in the identification of neo-epitopes that serve as private mutations for each patient's cancer as well as creates an opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens, enabling physicians to recognize and remove each patient's cancer cells.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead program is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Nurix

Venture Round in 2020
Nurix develops small molecule inhibitors for the treatment of proliferative and degenerative diseases. The company’s product engine leverages a deep mechanistic understanding of the UPS to deliver effective small molecule drug candidates with the potential to make a dramatic difference for patients. Nurix drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. The company discovers drugs that harness the body's natural process to control protein levels. Their focus is on developing drugs to treat cancer including the novel, small molecule immuno-oncology agents. Nurix was founded in 2009 by internationally recognized experts in the ubiquitin-proteasome field and is funded by leading life science investors, Third Rock Ventures, and The Column Group. The company is headquartered in San Francisco, California.

LifeMine Therapeutics

Series B in 2021
LifeMine Therapeutics, Inc., a biotechnology company, engages in the genomic discovery of new drug modalities from eukaryotic microbes. It utilizes an integrated genomically-enabled drug discovery platform to discover and develop a pipeline of new drugs from fungi. The company was incorporated in 2016 and is based in Cambridge, Massachusetts with an additional office in New York, New York.

Delfi Diagnostics, Inc.

Series A in 2021
Delfi Diagnostics detect cancer early, when it is most curable, using high precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. It was founded in 2019 and is headquartered in Baltimore, Maryland.

Mindstrong Inc.

Series C in 2020
Mindstrong Health develops comprehensive care pathways based on passively-collected, continuous and objective measures of cognitive function and mood. Solutions include a patient-facing app, a provider-facing product, and clinical services that leverage its telehealth enabled measurement science and engagement platform. Mindstrong is partnered with leading organizations committed to advancing medical innovation and improving healthcare delivery for patients, including pharmaceutical companies, large payers and providers, large employers, and state and county governments, in addition to top-tier academic institutions for clinical research.

Affinivax

Series C in 2021
Affinivax, Inc., a biotechnology company, focuses on developing multiple antigen presenting system (MAPS) technology based vaccines that provide protection against various infectious diseases afflicting children and adults around the globe. Its MAPS enables the binding of protective polysaccharides and proteins in a single vaccine and induces a protective immune response. The company develops its vaccine programs to target various pathogens, such as streptococcus pneumoniae (pneumococcus), bacterial nosocomial infections, salmonella typhi, and staphylococcus aureus. Affinivax, Inc. was incorporated in 2014 and is based in Lexington, Massachusetts.

Kira Pharmaceuticals

Series B in 2021
Kira Pharmaceuticals is a developer and researcher of antibody drugs and immunoantibody therapy. The company is mainly engaged in the research, development and production of antibody medicine to treat various diseases, providing healthcare patients with better treatments and therapy.

Orchard Therapeutics plc

Series C in 2018
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company’s gene therapy approach seeks to transform a patient’s hematopoietic stem cells into a gene-modified drug product to treat the patient’s disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company’s clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Theseus Pharmaceuticals

Series B in 2021
Theseus Pharmaceuticals is a Technology based company.

Tempest Therapeutics

Series B in 2018
Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor immunity pathways. The company has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response. Tempest Therapeutics was established in 2011 and is headquartered in San Francisco, California.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company’s second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.

Jounce Therapeutics, Inc.

Series B in 2015
Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce’s proprietary product engine is driving this transformational approach, which has the potential to drive significantly more durable responses to treatment, extending and improving patients’ quality of life. Founded by world leaders in immunobiology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures.

Keros Therapeutics, Inc.

Series C in 2020
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company’s lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.

Solid Biosciences

Series C in 2017
Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company’s lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to derive functional dystrophin protein expression in patients’ muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits. Solid Biosciences Inc. has strategic collaboration with Ultragenyx to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

SutroVax

Series D in 2020
Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).

Aduro BioTech

Series D in 2015
Aduro Biotech is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies that are designed to harness the body's natural immune system for the treatment of patients with challenging diseases. It was founded in 2000 and headquartered in Berkeley, California.
Decibel Therapeutics is a developer of hearing disorder therapeutics intended to protect, repair and restore hearing. The company's therapeutics have provided insights into the link between hearing dysfunction and inner ear pathology and it has capabilities to encompass animal models, drug delivery to the inner ear, imaging, inner ear PK/PD modeling and measurement, bioinformatics, genetics and target identification, enabling patients to experience hearing loss therapies with different forms of hearing disorders for their recovery.

Genomics PLC

Series B in 2018
Genomics PLC develops algorithms and software solutions that focus on cancer, microbes, and rare diseases. Its solutions allow governments and healthcare providers to transform healthcare provisions for their citizens and members; pharmaceutical and biotechnology clients to de-risk the drug development process; clinicians and doctors to improve diagnoses and treatment options; and research laboratories and genome analysts to process results accurately. The company was incorporated in 2014 and is based in Oxford, United Kingdom.

DNAnexus

Series E in 2018
DNAnexus combines expertise in cloud computing and bioinformatics to create the global network for genomic medicine. DNAnexus provides security, scalability and collaboration for enterprises and organizations that are pursuing genomic-based approaches to health in order to accelerate medical discovery. DNAnexus is supporting customers around the world that are tackling some of the most challenging and exciting opportunities in human health. It was founded in 2009 and is based in Mountain View, California.

10X Genomics, Inc.

Series B in 2014
10x Genomics is creating revolutionary DNA sequencing technology to help researchers better identify subtle variations that are overlooked by technologies that shred biological samples into tiny fragments before sequencing the short stretches and using computers to assembling them into a genome.

GenapSys, Inc.

Series C in 2019
GenapSys is actively looking to partner with local health agencies and researchers to arm researchers with access to the insight afforded by sequencing. With its sequencing technology, the company aims to help support the control and limit the spread of current and future outbreaks. The device can run off of a standard power source and is small enough to fit in the back of a truck or be deployed at hospitals, airports, and public transportation hubs for quick results on virus samples. It was founded in 2010 and headquartered in Redwood City, California.

Tasso

Series A in 2020
Tasso Inc., a healthcare company, develops a clinical-grade, at-home, and self-sampling blood collection devices. It offers on demand devices that allow people to collect blood with the push of a button from the comfort and privacy of their home, and then mail the samples back to a qualified laboratory for analysis. Tasso Inc. was founded in 2014 and is headquartered in Seattle, Washington.

Intarcia Therapeutics

Series E in 2016
Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.
A peloton is a team of bicyclists who achieve great efficiency of motion through cooperative action. It is also the root of platoon, a nimble military unit with capabilities that exceed the sum of its component parts. Founded by Chairman of Biochemistry Steven L. McKnight of UT Southwestern Medical Center, Peloton Therapeutics represents a unique combination of innovative science, strong financial support from the Cancer Prevention Research Institute of Texas (CPRIT), and seasoned investors and management. Working in close collaboration with scientists at UT Southwestern, Peloton is advancing a promising discovery and development pipeline, comprised of several small molecule-based programs, each with a distinct target and mechanism of action. Peloton's vision is to become a major biotech company in Dallas with a passion for discovering and developing novel cancer drugs.

Pharvaris B.V.

Series C in 2020
Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study. The co-founders of Pharvaris include an inventor of icatibant and the leadership from Jerini AG that developed icatibant for the treatment of HAE, now sold by Takeda under the brand name Firazyr®.

Sequenta

Series C in 2013
Sequenta is a venture funded biotech company dedicated to the discovery and development of clinical diagnostics based on a revolutionary new platform for understanding immune system status. A profound revolution in the cost of DNA sequencing has enabled the company to develop brand new approaches to measuring the most variable part of the human genome: the immune cell receptor genes. The incredible diversity created by these genes are at the heart of a large number of conditions critical to human health and disease allowing the company to be in a position to inform a large number of clinical decisions using a single powerful assay. The company was founded in 2008 by entrepreneurs who previously founded ParaAllele BioScience, a successful startup company sold to Affymetrix in 2005.

AveXis

Series D in 2015
Based in Dallas, Texas, AveXis is a clinic-ready, synthetic biology platform company. AveXis has, at its core, a desire to establish unique industry and research alliances which will bring innovative treatments to people with unmet medical needs. Our work in spinal muscular atrophy (SMA), a rare/orphan disease, is our first focus.
VenatoRx Pharmaceuticals, Inc., a pharmaceutical company, discovers and develops anti-infective agents. The company provides various antibacterial agents. It focuses on addressing resistant hospital and community bacterial infections, including difficult-to-treat infections caused by MRSA, Pseudomonas spp, and Salmonella spp. The company was founded in 2010 and is based in Malvern, Pennsylvania.

Audentes Therapeutics

Series C in 2015
Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

DNAnexus

Series F in 2019
DNAnexus combines expertise in cloud computing and bioinformatics to create the global network for genomic medicine. DNAnexus provides security, scalability and collaboration for enterprises and organizations that are pursuing genomic-based approaches to health in order to accelerate medical discovery. DNAnexus is supporting customers around the world that are tackling some of the most challenging and exciting opportunities in human health. It was founded in 2009 and is based in Mountain View, California.

Maze Therapeutics

Series A in 2019
Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines. The company's translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, functional genomics and an array of drug discovery approaches.and its also reveals modifier genes that confer protection and provides deeper understanding of the target biology and how these targets can be targeted with drug therapies, enabling patients with protection against diseases.

Remix Therapeutics

Series A in 2020
Remix Therapeutics Inc. engages in the biotech research and development business. It discovers and develops various novel therapeutic RNA processing modulators to target various undruggable disease drivers. The company also offers biology platform to identify and prioritize targets with therapeutically-tractable intervention points in RNA processing. Its REMseq platform validates targets and chemical matter discovery and optimization. The company was founded in 2018 and is based in Cambridge, Massachusetts.

Tarsa Therapeutics, Inc.

Series B in 2014
Tarsa Therapeutics, Inc. develops therapies for the treatment and prevention of osteoporosis and related bone diseases in women. It develops TBRIA, an oral formulation of salmon calcitonin used in the treatment of postmenopausal osteoporosis. The company offers clinical programs, such as osteoporosis treatment and osteoporosis prevention programs. Tarsa Therapeutics, Inc. was formerly known as Boneco, Inc. The company was founded in 2009 and is based in Philadelphia, Pennsylvania.

Evonetix Ltd

Series B in 2020
evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniques we are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines.

TP Therapeutics

Venture Round in 2018
Turning Point Therapeutics, Inc. is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. We are focusing on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity.
Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients. The company develops a proprietary product engine that employs to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that leads to physical impairments and disability. It is focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases.

LifeMine Therapeutics

Series A in 2017
LifeMine Therapeutics, Inc., a biotechnology company, engages in the genomic discovery of new drug modalities from eukaryotic microbes. It utilizes an integrated genomically-enabled drug discovery platform to discover and develop a pipeline of new drugs from fungi. The company was incorporated in 2016 and is based in Cambridge, Massachusetts with an additional office in New York, New York.
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.

Wave Life Sciences

Series B in 2015
WaVe Life Sciences is leading a revolution in nucleic acid therapeutics and was founded on the core principle that medicines should possess precisely controlled molecular structures. We and our strategic partners are advancing a portfolio of stereopure drug candidates that target underlying biology across a wide range of human diseases. WaVe maintains R&D facilities in Boston and Japan and was founded by two world-renowned scientific leaders, Gregory Verdine and Takeshi Wada. Dr. Verdine is an Erving Professor of Chemistry in the Harvard University Departments of Stem Cell and Regenerative Biology, Chemistry and Chemical Biology, and Molecular and Cellular Biology. Dr. Wada is a professor at Tokyo University of Science, Faculty of Pharmaceutical Sciences and Department of Medicinal and Life Science.

Aimmune Therapeutics

Series B in 2015
Aimmune Therapeutics is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.

Bit Bio

Series A in 2020
Elpis Biomed aims to become a leading, global supplier of in vitro cell types for academic research and commercial drug discovery & development purposes. The cells could provide an alternative to the limited supply of primary cells and replace animal studies in other cases. Elpis Biomed’s proprietary technology allows rapid generation of highly mature, differentiated cell types at unmatched purity. The process is scalable with the potential to expand product offering with additional cell-types in the neuro-mesoderm focus area. Initial products will be cortical neurons, oligodendrocytes and skeletal muscle cells to be sold to academic research groups and pharma/biotech customers.

Kinnate Biopharma

Series B in 2019
Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers. Its mission is to expand the reach of targeted therapeutics by developing products for underserved populations. The company utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine. Its programs include candidates in preclinical development for cancers that are driven by specific oncogenic alterations in either the BRAF kinase gene or in the FGFR2 and FGFR3 kinase genes.

Cerevance

Series B in 2020
Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle the early onset of various neurological diseases.

SomaLogic

Series A in 2020
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

SutroVax

Series C in 2018
Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).

EverlyWell

Series D in 2020
EverlyWell is a digital health platform that provides at-home health tests and lab results. Tests includes metabolism, food sensitivity, cardiovascular, inflammation, cholesterol and lipids, sleep and stress, and many more. EverlyWell ships the kit to your home, you send your sample to an EverlyWell lab, and you receive your clear results online. Founded in 2015, the company is based in Austin, Texas.

Protagonist Pty Ltd

Series C in 2015
Protagonist Pty Ltd. develops novel therapeutics for inflammatory and metabolic conditions. The company also involves in the discovery of peptide and small molecule compounds that mimic or inhibit therapeutically-relevant protein-protein interactions. In addition, it focuses on the discovery of drug candidates for targets previously resistant to small molecule discovery (protein-protein interactions), and on designing and constructing arrays of molecules that sample biologically-relevant regions of chemical diversity. Protagonist Pty Ltd was formerly known as Cytokine Mimetics Pty Ltd. The company was founded in 2001 and is based in Brisbane, Australia. Protagonist Pty Ltd operates as a subsidiary of Protagonist Therapeutics, Inc.

Nexvet Australia Pty Ltd

Series B in 2014
Nexvet Australia Pty Ltd, a biopharmaceutical company, develops biological therapies for companion animals. It develops drugs in the areas of chronic pain, immune oncology, chronic inflammation, and allergy. Nexvet Australia Pty Ltd was formerly known as Nexvet Biopharma Pty Ltd. The company was founded in 2010 and is based in Melbourne, Australia with a biopharmaceutical manufacturing facility in Tullamore, Ireland. Nexvet Australia Pty Ltd operates as a subsidiary of Zoetis Inc.

Relay Therapeutics

Series C in 2018
Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.The company's platform detects and characterizes interactions that occur anywhere on a protein and combines computational methods with experimental approaches across the fields of structural biology, biophysics and chemistry, enabling pharmaceutical companies to solve and design therapies against complex diseases like cancer and others.

Inscripta, Inc

Series C in 2018
Inscripta, Inc. operates as a gene editing technology company. The company engages in developing CRISPR enzymes (MADzymes) for precision gene editing. Inscripta, Inc. was formerly known as Muse Biotechnology, Inc. The company was founded in 2015 and is based in Boulder, Colorado. It has additional offices in Pleasanton and San Diego, California.

Tarsa Therapeutics, Inc.

Series B in 2012
Tarsa Therapeutics, Inc. develops therapies for the treatment and prevention of osteoporosis and related bone diseases in women. It develops TBRIA, an oral formulation of salmon calcitonin used in the treatment of postmenopausal osteoporosis. The company offers clinical programs, such as osteoporosis treatment and osteoporosis prevention programs. Tarsa Therapeutics, Inc. was formerly known as Boneco, Inc. The company was founded in 2009 and is based in Philadelphia, Pennsylvania.

Mindstrong Inc.

Series B in 2018
Mindstrong Health develops comprehensive care pathways based on passively-collected, continuous and objective measures of cognitive function and mood. Solutions include a patient-facing app, a provider-facing product, and clinical services that leverage its telehealth enabled measurement science and engagement platform. Mindstrong is partnered with leading organizations committed to advancing medical innovation and improving healthcare delivery for patients, including pharmaceutical companies, large payers and providers, large employers, and state and county governments, in addition to top-tier academic institutions for clinical research.

10X Genomics, Inc.

Series C in 2016
10x Genomics is creating revolutionary DNA sequencing technology to help researchers better identify subtle variations that are overlooked by technologies that shred biological samples into tiny fragments before sequencing the short stretches and using computers to assembling them into a genome.

Ardelyx, Inc.

Post in 2015
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company’s lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.

Inscripta, Inc

Series C in 2018
Inscripta, Inc. operates as a gene editing technology company. The company engages in developing CRISPR enzymes (MADzymes) for precision gene editing. Inscripta, Inc. was formerly known as Muse Biotechnology, Inc. The company was founded in 2015 and is based in Boulder, Colorado. It has additional offices in Pleasanton and San Diego, California.

Insitro

Series A in 2018
Insitro is a operator of a data-driven drug discovery and development company that uses machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company uses state-of-the-art technologies from Bioengineering enabling it to generate high-throughput, functional genomic data sets and aligning them with patient data via a novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.

DNAnexus

Series G in 2020
DNAnexus combines expertise in cloud computing and bioinformatics to create the global network for genomic medicine. DNAnexus provides security, scalability and collaboration for enterprises and organizations that are pursuing genomic-based approaches to health in order to accelerate medical discovery. DNAnexus is supporting customers around the world that are tackling some of the most challenging and exciting opportunities in human health. It was founded in 2009 and is based in Mountain View, California.
Decibel Therapeutics is a developer of hearing disorder therapeutics intended to protect, repair and restore hearing. The company's therapeutics have provided insights into the link between hearing dysfunction and inner ear pathology and it has capabilities to encompass animal models, drug delivery to the inner ear, imaging, inner ear PK/PD modeling and measurement, bioinformatics, genetics and target identification, enabling patients to experience hearing loss therapies with different forms of hearing disorders for their recovery.
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer. It is an independent, private biotechnology company. The founding of Alexo Therapeutics was based upon technology invented by Aaron Ring, K. Christopher Garcia, Kipp Weiskopf, Aron Levin, and Irving Weissman at Stanford University. This discovery involves soluble versions of signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with significantly greater affinity than natural SIRPα.1.

Replimune Group

Series B in 2017
Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company’s lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead program is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Inscripta, Inc

Series B in 2017
Inscripta, Inc. operates as a gene editing technology company. The company engages in developing CRISPR enzymes (MADzymes) for precision gene editing. Inscripta, Inc. was formerly known as Muse Biotechnology, Inc. The company was founded in 2015 and is based in Boulder, Colorado. It has additional offices in Pleasanton and San Diego, California.

Ivantis Inc.

Series B in 2014
Ivantis, Inc. is a company focused on developing an innovative treatment for Glaucoma. It is their goal to develop a less invasive, more effective option for the 60+ million people worldwide suffering from Primary Open Angle Glaucoma. As they successfully address this initial goal, it is then there intention to focus on innovative development for the treatment of other debilitating diseases within ophthalmology.

WaveTec Vision

Series D in 2013
WaveTec Vision is a small company with a big idea – and the ability and the team to achieve it. Their proprietary intraoperative aberrometer system ORange will transform and advance the emerging convergence of refractive and cataract surgery. It was founded in 1997 and headquartered in Aliso Viejo, California.

HealthVerity

Series C in 2019
HealthVerity is a provider of technologies and software tools that enable healthcare providers, such as Pharmaceutical manufacturers, Hospitals and Payers, to discover, license and integrate patient data from a wide range of traditional and emerging data sources to build the optimal patient data set. It serves as the foundation for the rapid creation, exchange, and management of healthcare and consumer data in a fully-interoperable, privacy-protecting manner. Advantaged by highly sophisticated identity resolution and matching capabilities, HealthVerity aims to increase transparency and activate deeper insights across the healthcare industry. It was founded in 2014 and is headquartered in Philadelphia, Pennsylvania.

Intellia Therapeutics

Series B in 2015
Intellia Therapeutics was formed in 2014 to lead the industry in one of the most promising new areas of therapeutic development: gene editing and repair using CRISPR-Cas9 technology. Intellia holds exclusive access to one of the most comprehensive intellectual property platforms available for the therapeutic use of CRISPR-Cas9. The company is advancing a broad pipeline toward clinical development, including ex vivo and in vivo approaches. Intellia closed a Series A round in 2014 led by Atlas Venture and Novartis.

Kinnate Biopharma

Series A in 2018
Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers. Its mission is to expand the reach of targeted therapeutics by developing products for underserved populations. The company utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine. Its programs include candidates in preclinical development for cancers that are driven by specific oncogenic alterations in either the BRAF kinase gene or in the FGFR2 and FGFR3 kinase genes.

Cullinan Management, Inc.

Series C in 2020
Cullinan Oncology is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.

Intarcia Therapeutics

Series D in 2014
Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.

Arcus Biosciences, Inc.

Series C in 2017
Arcus Biosciences is biotech company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. Arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the San Francisco bay area, in the heart of the world’s largest biotechnology research hub.

Juvenescence

Seed Round in 2018
Juvenescence Limited is a British Virgin Islands-based holding company that invests in human aging and longevity. Juvenescence has raised USD $111M to build an ecosystem and pipeline of assets targeting aging, age-related disease, and regeneration. Juvenescence believes that recent scientific and medical advances will enable the development of therapeutics that meaningfully extend human healthspan and eventually lifespan. A meaningful increase in lifespan in the already aging world will have profound implications on all sectors of society, and in particular healthcare, education, insurance, and leisure. The company creates and partners with new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures with the foremost longevity scientists and leading research institutions. Their work is based on a novel scientific understanding of the underlying biological causes of aging, to create evidence-based therapeutics that can treat diseases of aging. Juvenescence's goal is to extend both lifespan and healthspan, by developing therapeutics that slow aging and promote juvenescence.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company’s second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.